23 March 2017
Associate Professor Elgene Lim, breast cancer researcher at the Garvan Institute of Medical Research, The Kinghorn Cancer Centre and medical oncologist at St Vincent’s Hospital, Sydney, is one of two inaugural recipients of the National Breast Cancer Foundation Endowed Chair Program.
The National Breast Cancer Foundation Endowed Chairs Program comprises two long-term 10 year research grants for a total value of $5 million, which includes a co-contribution from the recipients’ host institutions. A new and unique concept for breast cancer research in Australia, Endowed Chairs are designed to keep mid-career researchers in Australia and focused on research that will lead to the next major breakthrough.
A/Prof Lim and his team work to overcome resistance to the hormone treatments used on the largest subtype of breast cancer – estrogen receptor positive breast cancer. Over the next 10 years, Associate Professor Lim’s research program will look at new ways to overcome hormone resistance and to sensitise breast cancer to hormone therapies.
A/Prof Lim received his Endowed Chair at An Evening With The National Breast Cancer Foundation, an event held on the 16th March at Sydney Grammar School.
“Research funding is increasingly challenging in Australia, which had a major impact on the number of talented researchers in our country with great ideas who are limited by a lack of research investment,” said A/Prof Lim.
“The generous timeframe provided by the Endowed Chair funding gives my team, my collaborators and me a unique opportunity to pursue bold and more impactful projects,” he continued.
“For us, this is a remarkable opportunity. It gives us the confidence to pursue our research agenda, which ultimately aims to improve the lives of breast cancer patients. This forms the bedrock of my commitment to research.”
Professor David Thomas, Head of Garvan’s Cancer Division and Director of The Kinghorn Cancer Centre, said, “Garvan’s research relies on the generous support of the public and organisations such as the National Breast Cancer Foundation. I’m delighted that Elgene has been recognised for his outstanding translational breast cancer research and his vision to involve patients in the research process.”